Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) and ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.
Earnings & Valuation
This table compares Tandem Diabetes Care and ENDRA Life Sciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tandem Diabetes Care | $1.01 billion | 1.32 | -$204.71 million | ($3.07) | -6.38 |
| ENDRA Life Sciences | N/A | N/A | -$11.51 million | ($8.92) | -0.59 |
Profitability
This table compares Tandem Diabetes Care and ENDRA Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tandem Diabetes Care | -20.17% | -68.23% | -11.07% |
| ENDRA Life Sciences | N/A | -396.15% | -190.40% |
Institutional & Insider Ownership
1.2% of ENDRA Life Sciences shares are held by institutional investors. 1.9% of Tandem Diabetes Care shares are held by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Tandem Diabetes Care has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Tandem Diabetes Care and ENDRA Life Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tandem Diabetes Care | 1 | 9 | 8 | 1 | 2.47 |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
Tandem Diabetes Care presently has a consensus target price of $29.06, suggesting a potential upside of 48.31%. ENDRA Life Sciences has a consensus target price of $30.00, suggesting a potential upside of 472.52%. Given ENDRA Life Sciences’ higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Tandem Diabetes Care.
Summary
Tandem Diabetes Care beats ENDRA Life Sciences on 8 of the 14 factors compared between the two stocks.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
